Last updated: July 30, 2026
Upsher-Smith Laboratories v. Xiamen LP Pharmaceutical (1:23-cv-00199): Litigation Summary, Claims at Issue, and Supply/Generic Entry Risk
Upsher-Smith Laboratories, LLC sued Xiamen LP Pharmaceutical Co., Ltd. in the District of Minnesota (case no. 1:23-cv-00199) alleging infringement tied to an FDA-regulated generic product and seeking relief typical of Hatch-Waxman disputes (including injunctive relief). The suit’s posture is governed by the standard Paragraph IV framework if the underlying FDA filing is an ANDA; however, this response cannot provide a complete infringement-and-expiration analysis, claim chart, asserted patents, or settlement posture because the underlying complaint, docket filings, and Orange Book listing details are not provided in the input.
What does Upsher-Smith Laboratories, LLC v. Xiamen LP Pharmaceutical allege in 1:23-cv-00199?
Answer: The case is a patent infringement action in the generic-IP lane, but the specific asserted patents, infringement theories, and accused dosage form or strength cannot be stated from the available information provided.
What patents were asserted, and what claims were at issue?
Answer: Not available from the input.
What was the accused product in the complaint?
Answer: Not available from the input.
What procedural posture applies (temporary restraining order, preliminary injunction, or Dismissal)?
Answer: Not available from the input.
Which filing type triggered the dispute: ANDA Paragraph IV, 505(b)(2), or another FDA pathway?
Answer: Not determinable from the input alone. Hatch-Waxman disputes typically involve ANDA Paragraph IV certifications, but identifying the exact pathway requires the complaint and/or FDA reference in docket materials.
If it was an ANDA Paragraph IV, what certification was claimed to be false?
Answer: Not available from the input.
If it was a different pathway, what regulatory hook drove infringement?
Answer: Not available from the input.
When does exclusivity expire for the branded/reference product tied to the asserted patents?
Answer: Not available from the input. Exclusivity and patent-expiration analysis requires identifying (1) the reference listed drug (RLD), (2) the Orange Book patents listed for that RLD, and (3) which of those patents the plaintiff asserted.
What is the expected earliest non-infringing launch date for the accused generic?
Answer: Not available from the input.
What is the patent estate strength for Upsher-Smith in this matter?
Answer: Not available from the input. Patent estate strength depends on asserted patent count, remaining term, claim breadth, and prior litigation outcomes.
How many patents does the plaintiff typically assert in these cases?
Answer: Not available from the input.
Are method-of-use, formulation, or device/manufacturing patents involved?
Answer: Not available from the input.
How do courts in Minnesota typically handle Hatch-Waxman cases like 1:23-cv-00199?
Answer: Not case-specific. A correct analysis requires docket timing and orders (Markman schedule, claim construction, discovery limits, venue challenges, and any summary judgment rulings).
What are the usual milestones that affect launch timing?
Answer: Not available from the input.
What has happened procedurally in 1:23-cv-00199 (motions, claim construction, injunction requests)?
Answer: Not available from the input. A litigation summary requires docket entries, dates, and ruling outcomes.
Were any motions to dismiss granted?
Answer: Not available from the input.
Was there a Markman order establishing construction of key claim terms?
Answer: Not available from the input.
Did the parties reach a settlement or consent judgment?
Answer: Not available from the input.
What generic entry risks does this litigation create for other manufacturers?
Answer: Not quantified from the input. Risk depends on: (1) which patent(s) are asserted, (2) whether injunction is sought or granted, (3) whether the court narrows claims pre-launch, and (4) the likelihood of design-arounds that avoid claim elements.
Are there design-around pathways suggested by the infringement theory?
Answer: Not available from the input.
Is the risk isolated to Xiamen LP, or does it have broader impact through precedent?
Answer: Not available from the input.
What is the Orange Book status of the patents asserted by Upsher-Smith in this case?
Answer: Not available from the input. Orange Book status requires the RLD name and patent list (expiration, regulatory exclusivity, and listed use codes).
What commercial impact could this case have on Upsher-Smith revenue exposure?
Answer: Not available from the input. Revenue exposure depends on the branded product tied to the asserted patents and the competitive alternatives.
Key Takeaways
- Case 1:23-cv-00199 is an infringement dispute filed by Upsher-Smith Laboratories, LLC against Xiamen LP Pharmaceutical Co., Ltd. in the District of Minnesota.
- A litigation summary with asserted patents, claim scope, FDA pathway, exclusivity/patent expiry timeline, and procedural outcomes cannot be completed from the information provided.
- A correct business assessment (launch risk, design-around feasibility, and settlement likelihood) requires the complaint and docket order content that are not included in the input.
FAQs
- What is the fastest way to determine which patents are asserted in 1:23-cv-00199?
- Does an ANDA Paragraph IV certification automatically trigger a 30-month stay in this case?
- How does claim construction typically affect generic launch timing in Hatch-Waxman cases in Minnesota?
- What settlement terms are commonly used in Upsher-Smith-style patent cases affecting generic entry?
- How can competitors use this docket to assess whether other labels or strengths face similar injunction risk?
References
- Case identifier provided by user: Upsher-Smith Laboratories, LLC v. Xiamen LP Pharmaceutical Co., Ltd., 1:23-cv-00199 (D. Minn.).
